A significant development has been reported by Moderna and Merck. Their collaborative effort has yielded promising results.

A trial involving over a thousand patients showed positive outcomes regarding melanoma. The findings indicate that the vaccine may prevent the disease from recurring or spreading. Further information on this breakthrough is available from the companies.